Arterius Ltd is engaged in the development of an innovative polymer-based bioresorbable scaffold (BRS), more commonly known as a ‘stent’. The bioresorbable attribute aims to allow the stent to dissolve over time, before being absorbed by the body. Therefore, this will mean that there is no requirement to physically remove the stent.
Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to:
|Product||Life Sciences EIS|
|Aim of funding||Growth|
|HMRC Advanced Assurance received||Yes|
|Envisaged investor exit||4-5 years|
|Targeted return||In excess of 4x capital invested|